STORY FROM: Drugs & Medical Devices

9th Cir. Reinstates Incretin Mimetic MDL, Says Failure-To-Warn Claims Not Preempted Under Buckman

SAN FRANCISCO — A federal appeals court has reinstated the multidistrict litigation for incretin mimetic type 2 diabetes drugs, finding the presiding judge misapplied U.S. Supreme Court law in ruling that the plaintiffs’ allegations constituted “fraud-on-the-FDA” claims that are preempted by Buckman v. Plaintiffs’ Legal Committee.

In a Dec. 6 opinion, the 9th Circuit U.S. Court of Appeals found the plaintiffs’ claims were based upon a state-law requirement that imposes a duty on drug makers to warn the FDA, which parallels federal requirements. As such, the claims are not preempted, the appellate court found.

Plaintiffs allege they developed pancreatic cancer ...

Associated Documents

Registered User Login